Covid, study from South Africa: 'Omicron variant more resistant to vaccine but causes milder symptoms'
Omicron variant and vaccine: vaccination coverage against infection drops to 33% after two doses of Pfizer-Biontech
Omicron variant and the vaccine: ‘Omicron is more resistant to vaccines even though it causes milder symptoms’
This is one of the conclusions reached by a South African study conducted by Discovery Health, one of South Africa’s largest health insurers, which has the merit of having analysed 211,000 positive cases with the Omicron variant.
The variant therefore seems to pierce the vaccines, and in particular the study shows that after two doses of Pfizer-Biontech, the most widely used in South Africa, the vaccination coverage against contagion and therefore infection drops to 33%, a much lower percentage than for all the other variants investigated to date.
The risk of hospitalisation, however, remains high: ‘70% protection against complications of the disease’.
The conclusions of the South African study seem similar to those of another English pre-print study, which last week anticipated that the threshold of protection against the virus, at the level of infection, stops at 40%.
The South African study therefore returns a more negative figure, but is unable to give any information on the effectiveness of the third dose and the possibility that this might increase coverage.
Read Also:
Omicron Variant: What Is It And What Are The Symptoms Of The Infection?
Covid, Cooke (Ema): ‘We Have Contingency Plans For Omicron Variant’
Covid, Experts In Japan Confirm: ‘Omicron More Contagious But Symptoms Milder’